chemotherapy with temozolomide. All patients underwent two times FLT PET/CT. One was preformed within 1 week before the initiation of CRT and the other one was performed 4 weeks after start of CRT. A more than 25% reduction in tumor FLT uptake as measured by maximum standardized uptake value (SUV max ) during CRT was defined as a proliferative response. Results: At a median follow-up of 25 months, the median survival was 11.1 months and two-year survival rate was 11.1%. The progression-free survival was 6.3 months. There were 10 responders (55.6%) and 8 nonresponders (44.4%). Responders survived longer than nonresponders (12.0 vs 8.5 months; P Z 0.004). Progression-free survival for responders was also better than nonresponders (6.8 vs 3.5 months; P Z 0.028). Conclusion: FLT PET/CT seems to be predictive of overall survival and progression-free survival in high-grade glioma patients treated with postoperative CRT. For patients with no response, more aggressive individualized treatment should be adopted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.